FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Estimated average I	hurden								

0.5

hours per response:

Check this box if no longer subject to
Section 16. Form 4 or Form 5
obligations may continue. See
Instruction 1(h)

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person*  Van Plew Daniel P					RE	2. Issuer Name and Ticker or Trading Symbol REGENERON PHARMACEUTICALS INC [ REGN ]											5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director  Officer (give title Other (specify below) below)						
(Last) 777 OLD	,	irst) LL RIVER ROA	(Middle) D			3. Date of Earliest Transaction (Month/Day/Year) 12/20/2012												VP & Ge	n Mg	below) gr IOPS			
(Street) TARRYTOWN NY 10591					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)											Individual or Joint/Group Filing (Check Applicable Line)     X Form filed by One Reporting Person     Form filed by More than One Reporting Person						
(City)	(S	tate)	(Zip)														reisui	лі					
			le I - Noi			_			<u> </u>		Disp		-			_							
Da			Date	ransaction e onth/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year		<u>,</u>	Code (Instr.						5. Amount of Securities Beneficially Owned Following Reported		Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)				
										Code	v	Amount	(,	A) or D)	Price	Transa		ction(s) 3 and 4)			(IIISU. 4)		
Common Stock 12/20						2				M		2,050	0	A	\$10	5.8	6,834		D				
Common Stock																1,305			Ι .	By 401(k) Plan			
		7	able II -									sed of					wned			,			
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transactior Code (Instr 8)		of Deri Sec Acq (A) o Disp of (I	oosed D) tr. 3, 4	Exp	Date Exe piration pnth/Day	Date		7. Title and Amount of Securities Underlying Derivative Secur (Instr. 3 and 4)			D Si (li	8. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	e s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
					Code	v	(A)	(D)	Dat Exe	e ercisable		opiration	Title	1	Amoun or Numbe of Shares	r							
Incentive Stock Option (right to buy)	\$16.8	12/20/2012			М			2,050		(1)	12	2/17/2018	Comn		2,050		(2)	3,902		D			

## **Explanation of Responses:**

- 1. The stock option award (combined incentive stock option and non-qualified stock option) vests in four equal annual installments, commencing one year after the date of grant.
- 2. Exercisable date, exercise date, exercise price, purchase price, sales price, and/or expiration date is/are not applicable in this case.

<u>/s/\*\*Daniel P. Van Plew</u> <u>12/21/2012</u>

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.